What is Wellinks?
Based in New Haven, Connecticut, Wellinks operates at the intersection of medical technology and patient-centric care. The company provides a comprehensive, virtual-first COPD management system designed to break down barriers for patients suffering from chronic respiratory issues. By integrating virtual pulmonary rehabilitation, health coaching, and real-time monitoring through connected devices and a proprietary smartphone application, Wellinks effectively extends the reach of clinical care.
The firm's market position is defined by its focus on high-acuity chronic disease management, a segment increasingly prioritized by healthcare providers and insurers seeking to reduce hospital readmissions and improve patient outcomes. With a leadership team comprised of digital health veterans, Wellinks is effectively bridging the gap between clinical expertise and accessible, technology-driven health solutions.
How much funding has Wellinks raised?
Wellinks has raised a total of $49.8M across 3 funding rounds:
Private Equity
$795K
Series B
$19M
Series C
$25M
Private Equity (2016): $795K, investors not publicly disclosed
Series B (2019): $19M led by HighCape Capital
Series C (2021): $25M supported by Benslie, HighCape Capital, The Morningside Group, Connecticut Innovations, and Stonehenge Capital
Key Investors in Wellinks
HighCape Capital
HighCape Capital is a growth equity fund established in 2013, focused on assisting innovative Life Sciences companies in their transition to successful organizations. The firm leverages the extensive experience of its multidisciplinary team, which includes industry veterans with backgrounds in founding, financing, and leading Life Sciences companies.
The Morningside Group
Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge, and are effective in the local environment in which they operate.
Connecticut Innovations
Connecticut Innovations is the state's strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies scale.
What's next for Wellinks?
With the successful closure of this major enterprise-level funding, Wellinks is poised to scale its operations and expand its reach within the competitive digital health market. The strategic roadmap likely involves enhancing its connected device ecosystem and deepening its integration with existing healthcare provider networks to solidify its market presence. As the company transitions into its next phase of growth, the focus will remain on optimizing patient engagement metrics and demonstrating long-term clinical efficacy to further validate its virtual-first care model.
The continued support from institutional investors suggests a long-term outlook focused on sustainable growth and the potential for Wellinks to become a standard-bearer in the remote management of chronic respiratory diseases.
